A 1-Day Training Course Delivered By
Paul CraddyGraham Foxon

Dr. Paul Craddy & Dr. Graham Foxon

  • Founders of Remap Consulting, a specialist pharmaceutical pricing and market access consultancy.
  • Paul and Graham have supported many pharma companies in developing and implementing pricing and market access strategies, in many instances for rare diseases.
  • Dr. Paul Craddy's former experience includes global and European pricing and market access positions at Takeda/Nycomed and IMS/Cambridge Pharma.
  • Dr. Graham Foxon's former market access and pricing experience includes both consultancy at IMS and Adelphi Values, as well as senior positions at GSK, Ferring and a start-up biotech.


  1. The opportunities and challenges of Orphan and Rare Diseases from a market access perspective.
  2. Guidelines for your Rare Disease access strategy: timelines, country customisation, value pricing…
  3. The perspective of payers and regulators, and which evidence you will need to secure patient access at the right time and the right price.
  4. Lessons from real-world cases about what works well and what doesn’t in orphan drug pricing.
  5. How Managed Entry Agreements can facilitate patient access.
  6. The benefits and challenges of different types of early access programs.
  7. How to develop a convincing value proposition for your Rare Disease treatment.

Additional Benefits

  • To reinforce peer learning, the experts will use a small pre-course questionnaire (by email) and polling during the day to actively engage the whole audience throughout the course.
  • Real-life case studies will be used to illustrate the theory and in small groups you will put the key learnings into practice on a real-world case study.


Why You Should Attend

The Content: Treatments for Orphan and Rare Disease offer attractive business opportunities to pharma, but the path to patient access is paved with many challenges. To optimise market access, companies need to carefully plan and execute their market access development strategy, as well as the evidence base and the value proposition. This 1-day course discusses the critical success factors and many real-life cases.

The Experts: Graham and Paul have gained broad and deep expertise in developing and implementing market access and pricing strategies, also specifically for Orphan and Rare diseases. They have a knack for explaining complex matters in a clear and easy to comprehend way. Both are regular guest lecturers at universities and business schools, as well as speakers at international events and conferences.

The Strategic Market Access Planning for Orphan Drugs course is the only available public training course delivered by Dr. Paul Craddy & Dr. Graham Foxon on this topic.

Agenda of the Strategic Market Access Planning for Orphan Drugs course

For start and end times, please check Dates & Locations below.

Welcome & Audience Expectations (~30 min)

Opportunities and Challenges from an HTA & Pricing Perspective (~25 min)

  • Orphan drug vs. rare disease - what is the difference?
  • Why are pharmaceutical companies interested in orphan drugs/rare diseases?
  • Pricing of orphan drugs, is it really as good as we think?
  • Why are payers so uncertain about orphan drugs?

HTA for Orphan Diseases: Current Practices (~1 h)

  • Similarities and differences in HTAs of traditional and orphan drugs
  • HTA process for the evaluation of orphan drugs
  • The need for country customisation across EU5 and US
  • Health economic considerations for orphan drugs
  • What are HTA agencies doing to support orphan drug development?

Framework for Assessing Value of Orphan Drugs (~1 h 20 min)

  • A 6 step approach to developing your orphan drug access strategy
  • Defining your patient population and their unmet needs
  • The importance of understanding the current treatment options and patient management systems
  • Comparator selection: what to do and what not to do!
  • Determining appropriate outcomes, knowing the major hurdles and how to alleviate them
  • Challenges of demonstrating economic value of orphan drugs
  • Approaches for addressing the evidence gaps

Lunch Break

How to Price Rare/Orphan Disease Drugs (~ 30 min)

  • Key drivers needed to secure a commercially viable price for an orphan drug
  • Case study analysis of successful and unsuccessful orphan drug pricing
  • How to justify orphan drug prices, from unmet need to evidence of medical benefit
  • The impact of missing the mark on orphan drug pricing

Use of Managed Entry Agreements to Facilitate Patient Access (~30 min)

  • Why implement a managed entry agreement?
  • Types of managed entry agreements
  • Use of performance-based agreements for orphan drugs
  • Key trends and key considerations for companies launching orphan drugs

Securing Early Access for Rare Disease Treatments (~30 min)

  • What is early access?
  • Different processes available to companies to secure early patient access for orphan drugs
  • The benefits and challenges of each early access program and the considerations companies should make when deciding whether to instigate early access

Group Exercise: Developing an Optimal Access Strategy For an Orphan Drug (~1 h)

In small groups, participants will develop an optimal access strategy for a real-life orphan drug case study, utilising learnings from the course.

Considerations to Build a Successful Access Strategy for Your Orphan Drug (~30 min)

  • Key challenges in developing a value proposition for an orphan product
  • Emphasising the evidence and acknowledging the gaps
  • EU HTA considerations when developing an orphan drug access strategy
  • Key considerations when developing value propositions for orphan products

Summary (~15 min)


>> Click here if you wish to receive the PDF brochure of this course

Learning Methodology

This course is designed to stimulate interaction and optimally engage all participants by asking input prior to the course with a small pre-course questionnaire (by email), as well as with an interactive group exercise.
You will not only learn from the experts, but also from discussing issues and exchanging experiences with your peers from other companies and countries. The small class sizes of CELforPharma’s courses facilitate this kind of valuable interaction.

infoThe typical audience size of our courses ranges from 6 to 20 (max) participants.

Who Should Attend?

This course is designed for managers involved in the process of gaining optimal access of Orphan and Rare Diseases.

As this course is delivered by Dr. Paul Craddy & Dr. Graham Foxon from Remap Consulting, a leading pharma consultancy company, executives from other professional service agencies should request approval prior to registering for this course. Please contact Annelies Swaan, Director Business Operations, for more information (aswaan@celforpharma.com, tel +32 (0)2 709 01 42).


Past Participants

Below is a non-exhaustive list of past participants who have benefited from attending this course.


Job Title



Senior Global DirectorAlmirallSpain
Director - Global Access Strategy LeadAmgenSwitzerland
Consulting AssociateClinigenUnited Kingdom
Senior Marketing ManagerJazz PharmaceuticalsSwitzerland
Patient Access and Launch Excellence LeadSwedish Orphan BiovitrumRomania
New Product Planning Lead NordicsTakedaSweden



Dates & Locations

All live online CELforPharma courses are hosted in Zoom.

Our face-to-face courses take place at the Courtyard Marriott Brussels Hotel (Avenue des Olympiades 6, 1140 Brussels, Belgium), a top-class business hotel which is located 15 minutes from Brussels National Airport by complimentary hotel shuttle or taxi and 30 minutes by taxi from Brussels South train station (Thalys, TGV, Eurostar).​​​​

  • 24 May 2023, face-to-face in Brussels

    09:30 - 17 :00 CET (Brussels/Amsterdam/Paris)
  • 28 November 2023, face-to-face in Brussels

    09:30 - 17 :00 CET (Brussels/Amsterdam/Paris)


Hotel Booking Assistance

Having built a strong relationship with the Courtyard Marriott Brussels Hotel, CELforPharma has secured preferential room rates for our delegates who book their accommodation three weeks or more prior to the course. Upon your registration, we will help you make your hotel booking. For any assistance in this matter please do not hesitate to contact Kealeigh Steel, Senior Programme Coordinator (kealeigh.steel@celforpharma.com, tel +32 (0)2 709 01 45).

Included in the Registration Fee - for the live online course​

  • Access to a small-class (max 20 participants), expert led course in real-time, using an interactive platform for break-out rooms, whiteboard exercises, polling, plenary discussions and chats.
  • Course material, which will be provided to you in both digital format (by email) and in hard copy (by post, so you can make notes during the course).
  • Certificate of attendance signed by the experts and CELforPharma.


Included in the Registration Fee - for the face-to-face course

  • Participation in a small-class (max 20 participants), expert led face-to-face course with interactive group exercises and plenary discussions. You will have the opportunity to meet the expert(s) and discuss your own projects/issues during the breaks.
  • Course material, which will be provided to you in both digital format (by email) and in hard copy (so you can make notes during the course).
  • Coffee, tea & refreshments during the course.
  • Informal networking lunch.
  • Certificate of attendance signed by the experts and CELforPharma.


Group Discounts

Team discounts can be offered to 3 or more delegates from the same company.
Contact Annelies Swaan, Director Business Operations, (aswaan@celforpharma.com) for more details.


How to Register

  1. Click the "Register Here" button on this page.
  2. Choose a course date, then fill out your personal details and company / invoicing details.
  3. Choose to pay via bank transfer or by credit card (through a secure payment link, which you will receive together with the invoice).
  4. Click "Confirm Registration". You will be sent an automatic email confirming your registration followed by a personal email containing an invoice and further payment instructions.

For assistance in registering, raising a PO or invoicing, please do not hesitate to contact Kealeigh Steel.
(email: kealeigh.steel@celforpharma.com or call: +32 2 709 01 45)


Transfer & Cancellation Policy

Flexible Transfer

  • If a registrant cannot attend the scheduled course, he/she can avoid any cancellation charge by sending a suitable replacement participant.
  • Alternatively, the registrant can transfer once on a “space available” basis at no extra cost, until 3 weeks prior to the event, to another course of the same value held within one year of the original course date.

Registration Cancellation

  • Less than 14 days prior to the course date: registrant liable to pay the full invoiced registration fee.
  • Between 15 and 30 days prior to the course date: registrant liable to pay 50% of the invoiced registration fee.
  • More than 30 days prior to the course date: registrant liable to pay a cancellation fee of € 450 per registrant.
  • If a registrant postpones his/her participation to a future course, and cancels again, no refund can be claimed for registration fees.

Related Courses